Clinical trials: Malignant Histiocytoses
Lymphoma, B-Cell, Lymphoma
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- NCT05940272
- Testing
- Hematolo-GIST Training, Participants Appointment
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer Survivor, Cognitive/Functional Effects
Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction
RATIONALE: An educational and skills training program for the parent of a childhood cancer survivor with neurobehavioral dysfunction may help improve the child's school performance, thinking ability, and behavior.
- Conditions
- Cancer Survivor, Cognitive/Functional Effects, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00713505
- Testing
- educational intervention, psychosocial assessment and care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Diffuse Large-Cell B-cell, Diffuse, Large B-cell Lymphoma
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Background: MLN4924 is an experimental cancer drug. It may help kill lymphoma cells and make them more sensitive to chemotherapy. EPOCH R is a combination chemotherapy drug.
- Conditions
- Lymphoma, Diffuse Large-Cell B-cell, Diffuse, Large B-cell Lymphoma, Lymphoma, Diffuse Large-Cell, Large-Cell Lymphoma, Diffuse
- Trial name
- NCT01415765
- Testing
- MLN4924, Etoposide, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Quality of Life
- Trial name
- NCT00126477
- Testing
- cognitive assessment, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Fred Hutchinson Cancer Center
DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
- Trial name
- NCT07778212
- Testing
- Orelabrutinib Combined with Pola-R-CHP Regimen
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Leukemia, Lymphoma
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00087009
- Testing
- beta-glucan, rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumor, Central Nervous System Tumors
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia
- Trial name
- NCT00066248
- Testing
- cyproheptadine hydrochloride, megestrol acetate
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- University of South Florida
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
DLBCL - Diffuse Large B Cell Lymphoma
Glofitamab in Chinese Patients With R/R DLBCL
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
- Trial name
- NCT06481826
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Leukemia, Lymphoma
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as trimetrexate glucuronate and leucovorin, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Sarcoma
- Trial name
- NCT00002738
- Testing
- leucovorin calcium, trimetrexate glucuronate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Trial name
- NCT00309907
- Testing
- etanercept, methylprednisolone
- Where
- 26 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line.
- Trial name
- NCT07748364
- Testing
- Glofitamab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Joshua Brody
Lymphoma
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00059995
- Testing
- iratumumab
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
DALY II Japan/MB-CART2019.1 for DLBCL
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell…
- Trial name
- DALY II Japan (NCT07288879)
- Testing
- MB-CART2019.1
- Where
- 5 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Miltenyi Biomedicine GmbH
DLBCL - Diffuse Large B Cell Lymphoma
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R …
- Trial name
- NCT07389356
- Testing
- Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University